"Mid-Illinois Hematology & Oncology Associates have many locations throughout Illinois: Bloomington-Normal, Hopedale, Eureka, Pontiac, Clinton, Forrest, and Gibson City. Our staff include: Pramern Sriratana, MD, Hwan G. Jeong, MD, and John J. Migas, MD. In the late 1990's, BroMenn Healthcare and OSF Healthcare came together to create and support a comprehensive cancer center. Opened in 1999, the center was a result of the generosity of this community as 6.5 million dollars was donated for its creation. Nowhere else in Central Illinois, and rarely across the country, can you get the care of multiple physician specialties, the latest drug therapies, radiation treatment, and research protocols with a full complement of support services."

During the past decade, Mid Illinois Hematology & Oncology Associates, Ltd. conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 15 clinical trials were completed, i.e. on average, 250% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 8 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Illinois Hematology & Oncology Associates, Ltd." #1 sponsor was "National Cancer Institute (NCI)" with 7 trials, followed by "SWOG Cancer Research Network" with 7 trials sponsored, "Bristol-Myers Squibb" with 4 trials sponsored, "NSABP Foundation Inc" with 2 trials sponsored and "Accelerated Community Oncology Research Network" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Illinois Hematology & Oncology Associates, Ltd." #1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator, "Eastern Cooperative Oncology Group" with 3 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator and "North Central Cancer Treatment Group" with 3 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Mid Illinois Hematology & Oncology Associates, Ltd." are "Breast Cancer" (6 trials), "Prostate Cancer" (4 trials), "Breast Adenocarcinoma" (2 trials), "Breast Ductal Carcinoma In Situ" (2 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Mid Illinois Hematology & Oncology Associates, Ltd." in a lesser frequency.

Most popular intervention types in "Mid Illinois Hematology & Oncology Associates, Ltd." are "Drug" (25 trials), "Other" (11 trials), "Biological" (6 trials), "Radiation" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (6 trials), "Bevacizumab" (4 trials), "Paclitaxel" (4 trials), "Quality-of-Life Assessment" (4 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Mid Illinois Hematology & Oncology Associates, Ltd." are 17 trials for "All" genders, 10 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Mid Illinois Hematology & Oncology Associates, Ltd.". undefined are not yet recruiting, 1 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Mid Illinois Hematology & Oncology Associates, Ltd., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Mid Illinois Hematology & Oncology Associates, Ltd., 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".